PD 1

Drug Profile

PD 1

Alternative Names: Anti-dyskinesia therapeutic - BIO3 Research; PD-1

Latest Information Update: 25 Oct 2005

Price : $50

At a glance

  • Originator Bio3 Research
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Drug-induced dyskinesia

Most Recent Events

  • 12 Oct 2005 Discontinued - Phase-I for Drug-induced dyskinesia in Italy (unspecified route)
  • 06 Jul 2004 Bio3 Research is seeking worldwide partners for the development of PD 1
  • 06 Jul 2004 Phase-I clinical trials in Drug-induced dyskinesia in Italy (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top